Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis

dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorKaraagac, Mustafa
dc.date.accessioned2024-02-23T14:27:00Z
dc.date.available2024-02-23T14:27:00Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractAbiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.en_US
dc.identifier.doi10.1177/1078155218818250
dc.identifier.endpage2034en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue8en_US
dc.identifier.pmid31694496en_US
dc.identifier.scopus2-s2.0-85074625126en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2031en_US
dc.identifier.urihttps://doi.org/10.1177/1078155218818250
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14418
dc.identifier.volume25en_US
dc.identifier.wosWOS:000494855400030en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAbirateroneen_US
dc.subjectMetastatic Castration-Resistant Prostate Canceren_US
dc.subjectHemodialysisen_US
dc.titleAbiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysisen_US
dc.typeArticleen_US

Dosyalar